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Antibodies have grown in importance as medi-
cines over the more than 40 years since Köhler 
and Milstein first produced monoclonal con-
structs.1 However, the ability of human immuno-
deficiency virus (HIV) type 1 (HIV-1) to evade 
the humoral immune response has until recently 
thwarted the effective use of antibodies in this 
important disease. The extraordinary plasticity 
of the HIV envelope allows exceptional antigenic 
diversity, leading to the rapid escape of the virus 
from most antibody responses.
However, unique broadly neutralizing anti-
bodies (bnAbs) can evolve over years in some 
HIV-infected people. These bnAbs can recognize 
a wide array of viral envelope sequences, and 
advances in high-throughput technologies have 
allowed the isolation and cloning of the genes 
encoding these rare antibodies.2 Since these anti-
bodies were identified, they have been intensively 
studied. They are thought to be akin to signposts, 
in the sense that they point to a path that might 
be followed by a future HIV vaccine strategy by 
means of the induction of bnAbs that are capa-
ble of preventing HIV infection.3
Despite the breadth and potency of bnAbs, no 
single bnAb has been able thus far to protect 
against the vast array of viral variants that are 
present in infected persons. However, the work 
recently reported by Xu and colleagues4 repre-
sents an advance in the implementation of anti-
HIV bnAbs. The investigators methodically creat-
ed hybrid anti-HIV molecules containing at first 
two, and then three, broadly neutralizing do-
mains that bind the HIV envelope (Env) protein 
(Fig. 1). Xu and colleagues found that a trispecif-
ic broadly neutralizing HIV antibody that encodes 
three bnAb domains — targeting the site within 
the HIV envelope that is used to bind the CD4 
receptor, the membrane-proximal external region 
at the base of the envelope stalk, and the heavily 
glycosylated V1 and V2 variable envelope loops 
— could mediate potent protection in macaques 
that were challenged with an infectious hybrid 
simian–human immunodeficiency virus (SHIV) 
with an HIV envelope gene.
There are several advantages, and some poten-
tial pitfalls, to this novel approach. A single en-
tity is easier to test, produce, and implement than 
a mixture of three antibodies. Additional engi-
neering of the triple antibody — the introduc-
tion of variants into the genic region encoding 
the Fc portion of the antibody — could augment 
its binding to the neonatal Fc receptor. High af-
finity is associated with a longer half-life. How-
ever, the engineered nature of these antibodies 
has a downside: over the course of weeks, the 
recipient’s immune system may treat this novel 
molecule as foreign and produce anti-antibodies 
that reduce the desired immunotherapeutic effect. 
If this risk does not prove to be limiting, the tri-
specific antibody could come to play an impor-
tant role in grappling with the trifecta of unmet 
needs in the HIV pandemic: prevention, treat-
ment, and cure.
Xu et al. modeled the use of bnAbs to prevent 
the acquisition of HIV-1 infection using a non-
human primate model. Five days after the infu-
sion of the trispecific bnAb into eight macaques, 
a mixture of SHIVs was introduced intrarectally. 
None of the primates became infected, in con-
trast to one quarter to one third of the animals 
that were given single bnAbs. In complementary 
work, Julg and colleagues5 found that primates 
were fully protected from a challenge with a mix 
of two SHIV strains by the coadministration of 
two singly specific bnAbs, in which each virus 
was sensitive to one of the antibodies. Much work 
remains in order to examine bnAbs as prophylaxis 
in the face of different routes of HIV challenge 
and in different populations and to compare 
Figure 1. A Three-Pronged Attack against the Human Immunodeficiency Virus (HIV).
Xu et al.4 recently found that infusing nonhuman primates with a trispecific antibody prevented infection on exposure to a hybrid simian–
human immunodeficiency virus (SHIV) with an HIV envelope gene. VRC01, PGDM1400, and 10E8 are potent antibodies that recognize 
different regions of the HIV envelope (Env) spike (Panel A) across a broad range of unique viral isolates. Their binding domains were 
combined into bispecific and trispecific antibodies (Panel B). Trispecific antibodies engage a broader range of viral particles than do 
monospecific and bispecific antibodies. They may also block infection more efficiently at mucosal surfaces and within deeper tissue 
(Panel C), neutralize a wider range of viral particles and cells in which the virus replicates (thus blocking viremia; Panel D), and identify 
persistently infected cells that have been induced to present antigen, allowing the clearance of these cells (Panel E). Xu et al. found that 
a trispecific broadly neutralizing antibody (bnAb) that encodes three bnAb domains targeting the site within the HIV envelope that is used 
to bind the CD4 receptor, the membrane-proximal external region (MPER) at the base of the Env stalk, and the heavily glycosylated V1 
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the relative success of this strategy with that of 
emerging long-acting antiretroviral drugs that 
are in development for the same purpose. In-
deed, the first clinical trial of a single bnAb to 
prevent the acquisition of HIV is under way 
(ClinicalTrials.gov number, NCT02568215). It is 
conceivable that the two approaches might be 
used in combination.
Similarly, broadly active and long-acting anti-
bodies may contribute to the deployment of 
long-acting antiretroviral therapy for the suppres-
sion of viremia in HIV-infected people, relieving 
the burden of adherence to a daily medication 
regimen in selected clinical situations. It may be 
more difficult for antibody therapy to totally 
contain viral replication once HIV infection is 
fully established, a situation that could allow 
antibody-escape mutations to develop over time. 
However, the availability of such bnAbs may con-
tribute importantly to the long-acting armamen-
tarium, which currently consists of only a hand-
ful of small-molecule drugs.
Finally, in the emerging field of HIV cure re-
search, tools to clear persistently infected cells 
are widely sought. Again, broad and potent anti-
Env antibodies that are capable of recognizing 
HIV-infected cells in vivo could direct effector 
cells to clear the latent reservoir, where viral 
antigens may be intermittently expressed or re-
vealed by specific HIV latency–reversing agents.6 
The ability of engineered antibodies to allow the 
simultaneous engagement of multiple epitopes 
is intriguing. In the case of the evasive HIV en-
velope, three may be the charm.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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